Presented Updated Clinical Data from Monotherapy Phase 1 Arm of RTX-240 Clinical Trial in Advanced Solid Tumors, Showing Clinical Responses with Favorable Tolerability in PD-(L)1 Refractory Disease ...
In November 2022, Rubius Therapeutics Inc (NASDAQ: RUBY) initiated a process to explore a range of strategic alternatives and planned to engage an investment bank to act as a strategic advisor. But ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Rubius Therapeutics is in the ...
Most cell therapies in development use a T cell or some other type of immune cell that’s engineered to perform a particular therapeutic task. Rubius Therapeutics makes its cell therapies from red ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Cambridge red blood cell ...
New Preclinical Data Presented at the FOCIS 2022 Annual Meeting Demonstrating Prevention of Type 1 Diabetes in a Stringent Preclinical Model Initial Clinical Results Expected in 2H’22 from Phase 1 Arm ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results